Find your future career

Join Grünenthal

experienced professionals

Stronger together:

Take up the challenge

Young Professionals

Come on board:

Kick start your career

Students

Get experience:

Internships for students

Logo Be!Grünenthal

We research, we develop, we bring true innovations to the marketplace. Is that also your goal? Do you also want to sustainably improve the lives of our patients?

Are you an innovative researcher, an unconventional thinker, a strategist, a visionary, a creative thinker, a pragmatist, or a go-getter? In short, are you a person who will rise to the challenge and make a difference?

Then we look forward to telling you more about Grünenthal—about us, what makes us tick, and how we can reach our goals together - every day, worldwide.

Annette, Communications Management, experienced professionals, Grünenthal, wide range of challenges, contribute to the company’s success

Annette, Communications Management

"There’s a wide range of challenges in an inspiring environment here. It’s great to contribute to the company’s success.”

What drives us and what we do - Stay up to date with all the happenings at Grünenthal

Our news


12 Jan 2017

Grünenthal introduces Latin America’s most modern women’s health products plant

Santiago de Chile, Chile – January 12th, 2017: Grünenthal, an R&D-driven, privately owned international pharmaceutical company with headquarters in Germany, announced the introduction of its new women’s health products plant today. Grünenthal invested USD 14.5 million to build the 1,150 m2 hormone plant, which is the company’s center of excellence for hormone production and the most modern in Latin America. The new facility will initially deliver high quality women’s health products to the Chilean market and – after the pending approval of the relevant authorities (INVIMA/ANVISA/COFEPRIS) – it will also provide products for other Latin American markets, including the biggest of the region: Brazil and Mexico. With this investment Grünenthal will improve the access of more than 168 million Latin American women to high quality health products.

More ...

16 Dec 2016

Grünenthal receives Breakthrough Therapy Designation from U.S. FDA for neridronic acid for the treatment of complex regional pain syndrome (CRPS), a debilitating orphan disease with high medical need

Aachen, Germany, and Pisa, Italy – 16 December 2016 – Grünenthal, an R&D-driven, privately held international pharmaceutical company with headquarters in Germany, and Abiogen Pharma, privately held Italian pharmaceutical company with headquarter in Pisa, Italy announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to neridronic acid, an investigational medicine, for the treatment of complex regional pain syndrome (CRPS), a serious, disabling orphan disease. Today, with no FDA- or EMA-approved drug treatments, there is a clear need for effective treatment options to address this significant unmet medical need. CRPS is a debilitating condition characterized by severe, continuous, burning pain often occurring in an extremity after injury or surgery. It is one of the most painful conditions a patient can experience1.

More ...

next [2]

awards